company background image
RENA

Renata DSE:RENATA Stock Report

Last Price

৳1.30k

Market Cap

৳139.8b

7D

0.08%

1Y

3.6%

Updated

09 Aug, 2022

Data

Company Financials +
RENATA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance3/6
Financial Health5/6
Dividends3/6

RENATA Stock Overview

Renata Limited manufactures, markets, distributes, and exports human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh and internationally.

Renata Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Renata
Historical stock prices
Current Share Price৳1,304.50
52 Week High৳1,380.00
52 Week Low৳1,248.27
Beta0.17
1 Month Change-1.92%
3 Month Change-3.78%
1 Year Change3.58%
3 Year Change46.20%
5 Year Change101.66%
Change since IPO41,734.56%

Recent News & Updates

Shareholder Returns

RENATABD PharmaceuticalsBD Market
7D0.08%0.3%0.4%
1Y3.6%-2.5%-9.5%

Return vs Industry: RENATA exceeded the BD Pharmaceuticals industry which returned -3.1% over the past year.

Return vs Market: RENATA exceeded the BD Market which returned -9.6% over the past year.

Price Volatility

Is RENATA's price volatile compared to industry and market?
RENATA volatility
RENATA Average Weekly Movement1.0%
Pharmaceuticals Industry Average Movement3.9%
Market Average Movement4.8%
10% most volatile stocks in BD Market6.7%
10% least volatile stocks in BD Market2.6%

Stable Share Price: RENATA is less volatile than 75% of BD stocks over the past 3 months, typically moving +/- 1% a week.

Volatility Over Time: RENATA's weekly volatility (1%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19728,957Syed S. Kabirhttps://www.renata-ltd.com

Renata Limited manufactures, markets, distributes, and exports human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh and internationally. Its pharmaceutical products include antimicrobials, anti-hypertensive, anti-angina, anti-diabetic, hair regrowth, eye-ear and topical preparation, antigout, NSAID, anti-spasmodic, steroid, anti-osteoporotic, anti-allergic, CNS, hormone, anti-cancer, oxytocic, anti-fibrinolytic, anti-asthma, expectorant, oral rehydration saline, narcotic analgesic, antipyretic/analgesic, antiemetic, anesthetic, antiviral, and other products. The company also offers lipid lowering, antiulcer, anti-parasitic and anti-protozoal, anti-fungal, anti-tuberculosis, and gastroprokinetic agents; and vitamins and minerals, and amino acid supplements.

Renata Fundamentals Summary

How do Renata's earnings and revenue compare to its market cap?
RENATA fundamental statistics
Market Cap৳139.83b
Earnings (TTM)৳5.54b
Revenue (TTM)৳32.06b

25.3x

P/E Ratio

4.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RENATA income statement (TTM)
Revenue৳32.06b
Cost of Revenue৳16.88b
Gross Profit৳15.19b
Other Expenses৳9.65b
Earnings৳5.54b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)51.66
Gross Margin47.37%
Net Profit Margin17.27%
Debt/Equity Ratio24.8%

How did RENATA perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

26%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is RENATA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RENATA?

Other financial metrics that can be useful for relative valuation.

RENATA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.5x
Enterprise Value/EBITDA17.9x
PEG Ratio1.4x

Price to Earnings Ratio vs Peers

How does RENATA's PE Ratio compare to its peers?

RENATA PE Ratio vs Peers
The above table shows the PE ratio for RENATA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average23.2x
SQURPHARMA Square Pharmaceuticals
10.2x11.4%৳189.3b
BXPHARMA Beximco Pharmaceuticals
12.1x13.1%৳69.5b
BEACONPHAR Beacon Pharmaceuticals
61xn/a৳57.1b
ACMELAB ACME Laboratories
9.4xn/a৳18.7b
RENATA Renata
25.3x17.8%৳139.8b

Price-To-Earnings vs Peers: RENATA is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the peer average (23.2x).


Price to Earnings Ratio vs Industry

How does RENATA's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

Price-To-Earnings vs Industry: RENATA is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the BD Pharmaceuticals industry average (21.8x)


Price to Earnings Ratio vs Fair Ratio

What is RENATA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RENATA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.3x
Fair PE Ratio16.3x

Price-To-Earnings vs Fair Ratio: RENATA is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the estimated Fair Price-To-Earnings Ratio (16.3x).


Share Price vs Fair Value

What is the Fair Price of RENATA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RENATA (BDT1304.5) is trading below our estimate of fair value (BDT1308.67)

Significantly Below Fair Value: RENATA is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies

Future Growth

How is Renata forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


17.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RENATA's forecast earnings growth (17.8% per year) is above the savings rate (3.6%).

Earnings vs Market: RENATA's earnings (17.8% per year) are forecast to grow faster than the BD market (11.5% per year).

High Growth Earnings: RENATA's earnings are forecast to grow, but not significantly.

Revenue vs Market: RENATA's revenue (13.5% per year) is forecast to grow faster than the BD market (9.1% per year).

High Growth Revenue: RENATA's revenue (13.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RENATA's Return on Equity is forecast to be high in 3 years time (21.2%)


Discover growth companies

Past Performance

How has Renata performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


15.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RENATA has a high level of non-cash earnings.

Growing Profit Margin: RENATA's current net profit margins (17.3%) are higher than last year (17.3%).


Past Earnings Growth Analysis

Earnings Trend: RENATA's earnings have grown by 15.1% per year over the past 5 years.

Accelerating Growth: RENATA's earnings growth over the past year (20.5%) exceeds its 5-year average (15.1% per year).

Earnings vs Industry: RENATA earnings growth over the past year (20.5%) underperformed the Pharmaceuticals industry 22.9%.


Return on Equity

High ROE: RENATA's Return on Equity (19.5%) is considered low.


Discover strong past performing companies

Financial Health

How is Renata's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: RENATA's short term assets (BDT16.5B) exceed its short term liabilities (BDT9.9B).

Long Term Liabilities: RENATA's short term assets (BDT16.5B) exceed its long term liabilities (BDT1.4B).


Debt to Equity History and Analysis

Debt Level: RENATA's net debt to equity ratio (13.6%) is considered satisfactory.

Reducing Debt: RENATA's debt to equity ratio has increased from 14% to 24.8% over the past 5 years.

Debt Coverage: RENATA's debt is well covered by operating cash flow (44%).

Interest Coverage: RENATA earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Renata current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


1.01%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: RENATA's dividend (1.01%) isn’t notable compared to the bottom 25% of dividend payers in the BD market (1.21%).

High Dividend: RENATA's dividend (1.01%) is low compared to the top 25% of dividend payers in the BD market (3.79%).


Stability and Growth of Payments

Stable Dividend: RENATA's dividends per share have been stable in the past 10 years.

Growing Dividend: RENATA's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (25.5%), RENATA's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: RENATA is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Syed S. Kabir

no data

Tenure

Mr. Syed S. Kaiser Kabir has been Managing Director and Chief Executive Officer of Renata Limited since 2002 and January 2002 respectively and serves as its Director. He serves as Chairman of Renata Agro I...


Leadership Team

Experienced Management: RENATA's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: RENATA's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Renata Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Renata Limited
  • Ticker: RENATA
  • Exchange: DSE
  • Founded: 1972
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ৳139.833b
  • Shares outstanding: 107.19m
  • Website: https://www.renata-ltd.com

Number of Employees


Location

  • Renata Limited
  • Plot No. 1
  • Section-7
  • Dhaka
  • 1216
  • Bangladesh

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/09 00:00
End of Day Share Price2022/08/08 00:00
Earnings2022/03/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.